期刊文献+

生物材料在心脏修复和再生中的应用

Application of Biomaterials in Cardiac Repair and Regeneration
下载PDF
导出
摘要 心血管疾病是全世界主要致死原因之一。人们对新的干预性治疗手段的需求与日俱增。虽然药物和手术治疗极大地改善了心血管疾病患者的生活质量,但人们还是需要价格更便宜、副作用更小的治疗手段。天然和合成生物材料无论是作为给药载体,还是替代支架的细胞外基质,在心脏修复和再生中都展现出巨大的潜力。本文探讨了目前治疗心血管疾病的几种方式和应用于上述疾病干预性治疗的生物材料;着重研究了导电聚合物在纠正局部缺血性心脏病引发的传导异常及其在心脏起搏器中应用的可能性,以改善心肌梗死状态下的传导路径。 Cardiovascular disease is a leading cause of death throughout the world. The demand for new thera- peutic interventions is increasing. Although pharmacological and surgical interventions dramatically improve the quality of life of cardiovascular disease patients, cheaper and less invasive approaches are always preferable. Biomaterials, both natural and synthetic, exhibit great potential in cardiac repair and regeneration, either as a carrier for drug delivery or as an extracellular matrix substitute scaffold. In this review, we discuss the current treatment options for several cardiovascular diseases, as well as types of biomaterials that have been investigated as potential therapeutic interventions for said diseases. We especially highlight investigations into the possible use of conductive polymers for correcting ischemic heart disease-induced conduction abnormalities, and the generation of biological pacemakers to im- orove the conduction oathwav in heart block.
出处 《Engineering》 SCIE EI 2016年第1期141-148,共8页 工程(英文)
基金 安大略心脏与卒中基金会向Ren-Ke Li提供的资金(G140005765)支持~~
关键词 缺血性心脏病 生物材料 再生 修复 心血管疾病 应用 治疗方案 传导阻滞 Myocardial infarction Heart regeneration Biomaterial Tissue engineeringStem cell
  • 相关文献

参考文献126

  • 1Public Health Agency of Canada [Internet]. Economic burden of illness in Canada, 2005-2008. [2014-06-20], Available from: http:[[www, phac-aspc. gc,ca/publicat/ebic-femc/2OO5-2008/index-eng.php.
  • 2Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al.; American Heart Association Statistics Committee and Stroke Statistics Sub- committee. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129(3):399-410.
  • 3Creaser JW, DePasquale EC, Vandenbogaart E, Rourke D, Chaker T, Fonarow GC. Team-based care for outpatients with heart failure. Heart Fail Clin 2015;11(3):379-405.
  • 4Heidenreich P. Heart failure prevention and team-based interventions. Heart Fail Clin 2015;11(3):349-58.
  • 5Larsen PM, Teerlink JR. Team-based care for patients hospitalized with heart failure. Heart Fail Clin 2015;11(3):359-70.
  • 6Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372(9):793-5.
  • 7Zhang J, Wilson GF, Soerens AG, Koonce CH, YuJ, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104(4):e30-41.
  • 8Masumoto H, lkuno I', Takeda M, Fukushima H, Marui A, Katayama S, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep 2014;4:6716.
  • 9lvashchenko CY, Pipes GC, Lozinskaya IM, Lin ZJ, Xu XP, Needle S, et al. Human-induced pluripotent stem cell-derived cardiomyocytes ex- hibit temporal changes in phenotype. Am J Physiol Heart Circ Physiol 2013;305(6):H913-22.
  • 10Miyagi Y, Chiu LL, Cimini M, Weisel RD, Radisic M, Li RK. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Bi- omaterials 2011 ;32( 5): 1280-90.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部